Skip to content

Distribution of ibogaine and noribogaine in a man following a poisoning involving root bark of the Tabernanthe iboga shrub.

Violeta Kontrimaviciūte, Olivier Mathieu, Jean-Claude Mathieu-Daudé, Paulius Vainauskas, Thierry Casper, Eric Baccino, Françoise M M Bressolle

Journal of Analytical Toxicology September 1, 2006 DOI: 10.1093/jat/30.7.434 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population 48-year-old Caucasian male with a history of drug abuse who died after ingesting Tabernanthe iboga root bark
Topics Ibogaine
Keywords Forensic toxicology Forensic analysis Poisoning investigation Toxicological analysis Plant compound Alkaloid Pharmacokinetics Drug distribution Tissue distribution Organ distribution Blood-brain barrier Systemic impact Metabolites Drug breakdown products
Citations 38
Key findings Ibogaine and noribogaine were distributed throughout most tissues, with highest concentrations in spleen, liver, brain, and lung, and both substances crossed the blood-brain barrier.

Abstract

In the present paper, we report for the first time the tissue distribution of ibogaine and noribogaine, the main metabolite of ibogaine, in a 48-year-old Caucasian male, with a history of drug abuse, found dead at his home after a poisoning involving the ingestion of root bark from the shrub Tabernanthe iboga. Ibogaine and noribogaine were quantified in tissues and fluids using a fully validated liquid chromatography-electrospray mass spectrometry method. Apart from cardiac tissue, ibogaine and noribogaine were identified in all matrices investigated. The highest concentrations were found in spleen, liver, brain, and lung. The tissue/subclavian blood concentration ratios averaged 1.78, 3.75, 1.16, and 4.64 for ibogaine and 0.83, 2.43, 0.90, and 2.69 for noribogaine for spleen, liver, brain, and lung, respectively. Very low concentrations of the two drugs were found in the prostatic tissue. Both ibogaine and noribogaine are secreted in the bile and cross the blood-brain barrier. Four other compounds were detected in most of the studied matrices. One of them was identified as ibogamine. Unfortunately, we were not able to positively identify the other three compounds because of the unavailability of reference substances. Two of them could possibly be attributed to the following oxidation products: iboluteine and desmethoxyiboluteine. The third compound could be ibogaline.

Comparable studies

Other case reports and case series on ibogaine, most cited first.

Study Year Design Participants
Treatment of acute opioid withdrawal with ibogaine. Patients undergoing opioid detoxification with ibogaine in non-medical settings 1999 Case series n = 33
A preliminary investigation of ibogaine: case reports and recommendations for further study. Individuals addicted to opiates 1994 Case series n = 7
Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine A 31-year-old woman 2009 Case study n = 1
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 31-year-old male military veteran with moderate alcohol use disorder 2018 Case study n = 1
Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report. 37-year-old female with severe opioid use disorder 2016 Case study n = 1

Citations in the library

Explore topics